Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management

Idorsia Pharmaceuticals Ltd. / Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management . Verarbeitet und übermittelt durch Nasdaq Corporate Solutions. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. Source: Globenewswire

• Idorsia to host an investor webcast to discuss the Phase 3 program today at 14:00hrs CEST

             
Allschwil, Switzerland - June 20, 2018
Idorsia Ltd (SIX: IDIA) today announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.

Hypertension, or high blood pressure, remains the most frequent addressable risk factor of cardiovascular morbidity/mortality outcomes, ahead of smoking and obesity, as reported by the 2015 Global Burden of Disease, Injuries, and Risk Factor Project collaborating with WHO.

Patients whose blood pressure remains high despite receiving at least three antihypertensive medications from different classes, including a diuretic, at maximal tolerated dose are categorized as having resistant hypertension. Patients with resistant hypertension are typically older and often suffer from obesity, sleep apnea, and/or diabetes mellitus.  Uncontrolled hypertension can lead to multiple cardiovascular and renal adverse outcomes, including stroke, heart disease, and kidney failure. These co-morbidities increase a patient's vulnerability and the complexity of their treatment.

Prof. John Chalmers, MD, Senior Director of The George Institute for Global Health and Professor of Medicine at the University of NSW Sydney, commented:
"Despite hypertension being a serious and growing problem around the world, there is surprisingly little research going on in the field. It has been over 30 years since an anti-hypertensive drug working via a new pathway has been brought to the market. Moreover, depending on the source of information, it is estimated that anywhere from 5 to 30 per cent of the hypertension patient population can be classified as treatment 'resistant' due to their uncontrolled blood pressure levels despite receiving multiple antihypertensive medications, though 'true resistant hypertension' may be much less frequent, of the order of 5 to 10%. There is an urgent public health need for additional therapies acting on pathways different from those currently used, in line with the underlying disease mechanism."